" 1. In selected patients undergoing PCI, shorter-duration DAPT (1–3 months) is reasonable, with subsequent transition to P2Y12 inhibitor monotherapy to reduce the risk of bleeding events (Level of Evidence A)".
"1. In patients with SIHD and normal left ventricular function, the routine use of chronic oral beta-blockers is not beneficial to reduce cardiovascular events after complete revascularization.(Level of Evidence:C-LD "
"1. In patients with atrial fibrillation who are undergoing PCI and are taking oral anticoagulant therapy, it is recommended to discontinue aspirin treatment after 1 to 4 weeks while maintaining P2Y12 inhibitors in addition to a non–vitamin K oral anticoagulant (rivaroxaban, dabigatran, apixaban, or edoxaban) or warfarin to reduce the risk of bleeding (Level of Evidence: B-R)"
" 2. In patients with atrial fibrillation who are undergoing PCI, are taking oral anticoagu-lant therapy, and are treated with DAPT or a P2Y12 inhibitor monotherapy, it is reasonable to choose a non–vitamin K oral anticoagulant over warfarin to reduce the risk of bleeding (Level of Evidence B-R)".
↑Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation, published online before print November 3, 2011, doi:10.1161/CIR.0b013e318235eb4d. Accessed November 3, 2011.
↑Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation, 106 (2002), pp. 3143–3421
↑A.M. Dattilo, P.M. Kris-Etherton Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis Am J Clin Nutr, 56 (1992), pp. 320–328
↑C. Baigent, L. Blackwell, J. Emberson et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta analysis of data from 170,000 participants in 26 randomised trials Lancet, 376 (2010), pp. 1670–1681
↑T.R. Pedersen, O. Faergeman, J.J. Kastelein et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA, 294 (2005), pp. 2437–2445
↑J.C. LaRosa, S.M. Grundy, D.D. Waters et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med, 352 (2005), pp. 1425–1435
↑MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet, 360 (2002), pp. 7–22
↑C. Baigent, L. Blackwell, Cholesterol Treatment Trialists' (CTT) Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet, 376 (2010), pp. 1670–1681
↑C.P. Cannon, E. Braunwald, C.H. McCabe et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med, 350 (2004), pp. 1495–1504
↑C.P. Cannon, B.A. Steinberg, S.A. Murphy et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol, 48 (2006), pp. 438–445
↑A.V. Chobanian, G.L. Bakris, H.R. Black et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension, 42 (2003), pp. 1206–1252
↑S.P. Whelton, A. Chin, X. Xin et al.Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials Ann Intern Med, 136 (2002), pp. 493–503
↑L.J. Appel, E.D. Frohlich, J.E. Hall et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association Circulation, 123 (2011), pp. 1138–1143
↑The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA 2003;289:178; JAMA 2004;291:2196] JAMA, 288 (2002), pp. 2981–2997
↑C. Duncan, M.J. Stein, S.R. Cummings Staff involvement and special follow-up time increase physicians' counseling about smoking cessation: a controlled trial Am J Public Health, 81 (1991), pp. 899–901
↑W. Rosser, I. McDowell, C. Newell Documenting smoking status: trial of three strategies Can Fam Physician, 38 (1992), pp. 1623–1628
↑S.R. Cummings, R.J. Richard, C.L. Duncan et al. Training physicians about smoking cessation: a controlled trial in private practice J Gen Intern Med, 4 (1989), pp. 482–489